Neurological complications during HIV infection
Jose M. Martinez-Navio
Exploration of Neuroprotective Therapy ›› 2021, Vol. 1 ›› Issue (1) : 19 -32.
Early in the course of infection, human immunodeficiency virus (HIV) is able to enter the central nervous system where it stablishes a permanent reservoir. Current antiretroviral therapies do not efficiently cross the blood-brain barrier and therefore do not reach the HIV located in the central nervous system. Consequently, HIV infection can often be associated with neurocognitive impairment and HIV-associated dementia. The purpose of this review is to brief the reader into the world of neurological complications arising from HIV infection. Mechanisms by which HIV directly or indirectly impairs the central nervous system are discussed, as well as other factors influencing or contributing to the impairment, and the animal models currently used to perform research on the topic.
HIV / neurological complications / HIV-associated neurocognitive disorders / dementia / inflammation
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
García F, Plana M, Vidal C, Cruceta A, |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
Kovalevich J, Langford D. Neuronal toxicity in HIV CNS disease. Future Virol. 2012; 7: 687-98. |
| [29] |
|
| [30] |
|
| [31] |
Mitra P. HIV neurocognitive disorders [Internet]. Sharman T, editor. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Apr 10]. Available from: https://www.statpearls.com/articlelibrary/viewarticle/20340/ |
| [32] |
|
| [33] |
Rezaie A, Parmar R, Rendon C, Zell SC. HIV-associated vacuolar myelopathy: a rare initial presentation of HIV. SAGE Open Med Case Rep. 2020; 8: 2050313X20945562. |
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
Sorce S, Myburgh R, Krause KH. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol. 2011; 93: 297-311. |
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
Mishra M, Taneja M, Malik S, Khalique H, |
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
Marchetti G, Tincati C, |
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med. 2014; 40: 43-52. |
| [90] |
|
| [91] |
Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, |
| [92] |
|
| [93] |
|
| [94] |
Faia C, Plaisance-Bonstaff K, Peruzzi F. In vitro models of HIV-1 infection of the Central Nervous System. Drug Discov Today Dis Models. 2020; 32: 5-11. |
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
Matsuda K, Riddick NE, Lee CA, Puryear SB, |
| [109] |
|
| [110] |
Sil S, Thangaraj A, |
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
/
| 〈 |
|
〉 |